176 related articles for article (PubMed ID: 33503190)
1. The mutational repertoire of uterine sarcomas and carcinosarcomas in a Brazilian cohort: A preliminary study.
da Costa LT; Dos Anjos LG; Kagohara LT; Torrezan GT; De Paula CAA; Baracat EC; Carraro DM; Carvalho KC
Clinics (Sao Paulo); 2021; 76():e2324. PubMed ID: 33503190
[TBL] [Abstract][Full Text] [Related]
2. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract][Full Text] [Related]
3. The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas.
Moukarzel LA; Ferrando L; Da Cruz Paula A; Brown DN; Geyer FC; Pareja F; Piscuoglio S; Papanastasiou AD; Fusco N; Marchiò C; Abu-Rustum NR; Murali R; Brogi E; Wen HY; Norton L; Soslow RA; Vincent-Salomon A; Reis-Filho JS; Weigelt B
Mol Oncol; 2021 Apr; 15(4):1024-1039. PubMed ID: 33021035
[TBL] [Abstract][Full Text] [Related]
4. Integrated Molecular Characterization of Uterine Carcinosarcoma.
Cherniack AD; Shen H; Walter V; Stewart C; Murray BA; Bowlby R; Hu X; Ling S; Soslow RA; Broaddus RR; Zuna RE; Robertson G; Laird PW; Kucherlapati R; Mills GB; ; Weinstein JN; Zhang J; Akbani R; Levine DA
Cancer Cell; 2017 Mar; 31(3):411-423. PubMed ID: 28292439
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience.
Erdogan EG; Yalta TD; Can N; Süt N; Taştekin E; Usta U; Puyan FÖ; Usturalı Keskin FE; Kurt BB
Indian J Pathol Microbiol; 2023; 66(3):449-455. PubMed ID: 37530323
[TBL] [Abstract][Full Text] [Related]
6. ERBB-2 gene overexpression and amplification in uterine sarcomas.
Amant F; Vloeberghs V; Woestenborghs H; Debiec-Rychter M; Verbist L; Moerman P; Vergote I
Gynecol Oncol; 2004 Dec; 95(3):583-7. PubMed ID: 15581967
[TBL] [Abstract][Full Text] [Related]
7. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
Liu Y; Weber Z; San Lucas FA; Deshpande A; Jakubek YA; Sulaiman R; Fagerness M; Flier N; Sulaiman J; Davis CM; Fowler J; Starks D; Rojas-Espaillat L; Lazar AJ; Davies GE; Ehli EA; Scheet P
Gynecol Oncol; 2018 Nov; 151(2):243-249. PubMed ID: 30194005
[TBL] [Abstract][Full Text] [Related]
8. Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma.
Ashley CW; Da Cruz Paula A; Ferrando L; Gularte-Mérida R; Sebastiao APM; Brown DN; Gazzo AM; Pareja F; Stylianou A; Abu-Rustum NR; Reis-Filho JS; Buehler D; Weisman P; Chiang S; Weigelt B
Histopathology; 2021 Aug; 79(2):176-186. PubMed ID: 33527450
[TBL] [Abstract][Full Text] [Related]
9. PTEN mutations in uterine sarcomas.
Amant F; de la Rey M; Dorfling CM; van der Walt L; Dreyer G; Dreyer L; Vergote I; Lindeque BG; Van Rensburg EJ
Gynecol Oncol; 2002 Apr; 85(1):165-9. PubMed ID: 11925138
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite instability in uterine sarcomas.
Amant F; Dorfling CM; Dreyer L; Vergote I; Lindeque BG; Van Rensburg EJ
Int J Gynecol Cancer; 2001; 11(3):218-23. PubMed ID: 11437928
[TBL] [Abstract][Full Text] [Related]
11. Pathologic and molecular features of uterine carcinosarcomas.
Lopez-Garcia MA; Palacios J
Semin Diagn Pathol; 2010 Nov; 27(4):274-86. PubMed ID: 21309261
[TBL] [Abstract][Full Text] [Related]
12. Molecular variations in uterine carcinosarcomas identify therapeutic opportunities.
Crane E; Naumann W; Tait D; Higgins R; Herzog T; Brown J
Int J Gynecol Cancer; 2020 Apr; 30(4):480-484. PubMed ID: 32114514
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathological and gene mutation characteristics of uterine carcinosarcoma].
Tu J; Xu JZ; Zhang YS; Deng LF
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(24):1864-1867. PubMed ID: 37357193
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new.
Hwang H; Matsuo K; Duncan K; Pakzamir E; Pham HQ; Correa A; Fedenko A; Mhawech-Fauceglia P
J Clin Pathol; 2015 Sep; 68(9):710-7. PubMed ID: 25991737
[TBL] [Abstract][Full Text] [Related]
15. Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss.
Lin DI; Hemmerich A; Edgerly C; Duncan D; Severson EA; Huang RSP; Ramkissoon SH; Connor YD; Shea M; Hecht JL; Ali SM; Vergilio JA; Ross JS; Elvin JA
Gynecol Oncol; 2020 May; 157(2):357-366. PubMed ID: 32156473
[TBL] [Abstract][Full Text] [Related]
16. Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature.
Murray S; Linardou H; Mountzios G; Manoloukos M; Markaki S; Eleutherakis-Papaiakovou E; Dimopoulos MA; Papadimitriou CA
Mutat Res; 2010 Apr; 686(1-2):68-73. PubMed ID: 20122944
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas.
Seidman JD; Chauhan S
Int J Gynecol Pathol; 2003 Jan; 22(1):75-82. PubMed ID: 12496702
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas.
Coosemans A; Nik SA; Caluwaerts S; Lambin S; Verbist G; Van Bree R; Schelfhout V; de Jonge E; Dalle I; Jacomen G; Cassiman JJ; Moerman P; Vergote I; Amant F
Eur J Cancer; 2007 Jul; 43(10):1630-7. PubMed ID: 17531467
[TBL] [Abstract][Full Text] [Related]
19. Integrated mutational landscape analysis of uterine leiomyosarcomas.
Choi J; Manzano A; Dong W; Bellone S; Bonazzoli E; Zammataro L; Yao X; Deshpande A; Zaidi S; Guglielmi A; Gnutti B; Nagarkatti N; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Jeong K; Zhao S; Buza N; Hui P; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Ardighieri L; Bilguvar K; Quick CM; Silasi DA; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Imielinski M; Schwartz PE; Alexandrov LB; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33876771
[TBL] [Abstract][Full Text] [Related]
20. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
Growdon WB; Roussel BN; Scialabba VL; Foster R; Dias-Santagata D; Iafrate AJ; Ellisen LW; Tambouret RH; Rueda BR; Borger DR
Gynecol Oncol; 2011 Apr; 121(1):212-7. PubMed ID: 21168197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
